Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 19/20 | 1.00 |
| ▸ | SRD5A2 | P31213 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2641280 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL7519255 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL2639525 | 1.00 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL7520592 | 0.93 | SRD5A1 (0.86) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL7520589 | 0.93 | SRD5A1 (0.86) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL7523351 | 0.91 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8794553 | 0.91 | SRD5A1 (0.85) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8794566 | 0.91 | SRD5A1 (0.85) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL7523345 | 0.91 | SRD5A1 (1.00) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL9022562 | 0.90 | SRD5A1 (0.81) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-03-27 | — | — | US | claimed |
| US-20240391883-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-11-28 | — | — | US | claimed |
| EP-4446301-A2 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2024-10-16 | — | — | EP | claimed |
| EP-3988541-B1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2024-06-26 | — | — | EP | claimed |
| EP-3442942-B1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2023-11-15 | — | — | EP | claimed |
| US-20220267283-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-08-25 | — | — | US | claimed |
| US-20220220558-A1 | METHODS AND SYSTEMS FOR PROGNOSIS OF A PATIENT'S RESPONSE TO TREATMENT OF ANDROGENETIC SKIN DISORDERS | GOREN ANDY OFER (US) | 2022-07-14 | — | — | US | claimed |
| US-11345670-B2 | Heterocyclic compounds for cancer imaging and treatment and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-05-31 | — | — | US | claimed |
| EP-3988541-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | British Columbia Cancer Agency Branch (CA) | 2022-04-27 | — | — | EP | claimed |
| US-20170056336-A1 | CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | claimed |
| US-20160068466-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-03-10 | — | — | US | claimed |
| US-9173939-B2 | Ester derivatives of androgen receptor modulators and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-11-03 | — | — | US | claimed |
| EP-0970105-B1 | PROCESS FOR PREPARING CARBOXAMIDO-4-AZASTEROIDS | PHARMACIA & UPJOHN SPA (IT) | 2002-02-27 | — | — | EP | claimed |
| EP-0970105-A1 | PROCESS FOR PREPARING CARBOXAMIDO-4-AZASTEROIDS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-01-12 | — | — | EP | claimed |
| WO-1999035161-A1 | PROCESS FOR PREPARING CARBOXAMIDO-4-AZASTEROIDS | PHARMACIA & UPJOHN SPA (IT) | 1999-07-15 | — | — | WO | claimed |
| JP-H10506411-A | — | — | 1998-06-23 | — | — | JP | claimed |
| EP-0607400-B1 | Fluorinated 17-beta substituted-4-aza-5-alpha- andostran-3one derivatives. | PHARMACIA & UPJOHN SPA (IT) | 1997-11-05 | — | — | EP | claimed |
| EP-0782582-A1 | EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5$g(a)-ANDROST-1-ENE-17$g(b)-CARBOXAMIDE | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-07-09 | — | — | EP | claimed |
| WO-1997004002-A1 | EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5α-ANDROST-1-ENE-17β-CARBOXAMIDE | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-02-06 | — | — | WO | claimed |
| WO-1994003475-A1 | FLUORINATED 17β-SUBSTITUTED 4-AZA-5α-ANDROSTAN-3-ONE DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1994-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100986-A1 | BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS | AR, SHBG, NR5A1 | SRD5A1 17/4885SRD5A2 29/4885LMNA 1844/4885 |
| US-20240391883-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | AR, KLK3, GNRHR | SRD5A1 10/4885SRD5A2 42/4885LMNA 1234/4885 |
| US-11345670-B2 | Heterocyclic compounds for cancer imaging and treatment and methods for their use | AR, KLK3, GNRHR | SRD5A1 10/4885SRD5A2 42/4885LMNA 1234/4885 |
| US-20220267283-A1 | HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE | AR, KLK3, GNRHR | SRD5A1 10/4885SRD5A2 42/4885LMNA 1234/4885 |
| US-20160068466-A1 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, ESRRA, KLK3 | SRD5A1 36/4885SRD5A2 42/4885LMNA 1651/4885 |
| US-20170056336-A1 | CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, MTOR, RICTOR | SRD5A1 65/4885SRD5A2 126/4885LMNA 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.